

-

-

-

” ”

03.01.19

:

. - ,
. - ,

, 2017

18 , 11 2 154 ,
60 312 . 372 ,
.

, .
- ,
.

,
”
- , 25.05.2017 .

26.07.2017 . 13:30 . ”
” -

.....

-
: www.mu-pleven.bg.

:

:

1.	5
2.	8
3.	9
4.	13
5.	30
5.	39
6.	41

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

AHA -

ASA -

DWI - Diffusion Weighted Imaging - DWI

FDA -

NIHSS - National Institutes of Health Stroke Scale

PFO - foramen ovale

PWI - Perfusion Weighted Imaging - PWI

rt-Pa -

1. _____

()

2002

ABCD (2)

ABCD

2,

7 90

[ABCD (2) 4.]

96%

40%

ABCDE⊕ ABCD 3-I,

ASPIRE

24-

Canadian TIA Score

-

7-

(DOT) Score

,

,

.

,

TOAST,

ASCO

ASCOD

,

- ASCOD

TOAST

,

ASCOD

35%

2014

” ”

-

-

,

:

,

foramen

ovale /

,

-

(Embolic Stroke of Undetermined Source - ESUS)

Chameleons.

- (TIA-mimics)

“ - ” TIA-

,

1997

.

-

-

10

48.5%

2. _____ :

2.1. _____ :

- _____ .

2.2. _____ :

1.

(3)

(> 3)

ABCD (2)

.

2.

.

3.

—

.

4.

.

5.

- ,

,

,

3.

3.1. :

3.1.1. :

3.1.2. :

3.1.3. :

50%

50%

3.1.4. : .11.2008 .12.2016

3.2. :

3.2.1. :

·
:
(), 24

·
· / ,
, 24 ,

·
· -
·

·
:
(), ().
(. , 2000 . , ,
2008) :

1.

1.1.

1.2. , -
·

2.

3.

4. ()

3.2.2. :
:
· : , ,
· ,

/ , () .
 .
 .
 . ABCD (2) .
 .
 .
 . 3.2.3. , :
 . - : , , (, HDL- , LDL-) .
 . - ,
 . , - .
 . -
 . () .
 . (. , 2011) .
 . - 12-

3.3. .
 IBM SPSS Statistics
 19.0. < 0.05.
 :
 () , Fisher χ^2 - -

, t- Student
 Mann-Whitney
 Kolmogorov-Smirnov
 Shapiro-Wilk -
 (One-Way ANOVA) -
 Post-hoc (HSD-
 Tukey), -
 ,
 -
 , Kappa (J. Cohen) -
 , .

4. _____ :

4.1.

. 130 ,
12

:

:

1.

2.

60 .

:

1.

2.

,

72-

3.

4.

60 .

(75%)

(53.1%), 70.68 ± 8.82 61 (46.9%) 69
 . 130 , 94 (72.3%)
 24
 36 (27.7%) – 48- 72- ().
 -
 (73.5±8.0 67.4±8.6 , p<0.001)
 (73.8%
 47.8%, p=0.003). : -
 , .
 : - 78

(60.0%), - 17 (13.1%) () - 35 (26.9%).

, 76 (58.5%)
, 26 (20.0%)
/ , 31 (23.8%)
38 (29.2%) - . 12-

99 (76.2%), 33 (25.4%), 36 (27.7%) 53 (40.8%).

20 (15.4%)
- ASA Dipyramidole .
85 (65.4%)
ASA (300 mg/) . 6 (4.6%)
- 3 Acenocoumarol 3 Dabigatran etexilate
(300 mg/) . 39 (30.0%)
ASA
Clopidogrel (75 mg/) .

84
(43) 46 41 -

($p > 0.05$).

ABCD (2)

ABCD (2) 4 5 ,

. 60 (46.2%) D (2) 4 . 70
 (53.8%) D (2) 5 .

D (2)

($p > 0.05$).

LDL- 5 53 , - 1.
 - 100%
 3.08% (4) 24
 76 , 48 - 25 48-
 - 29. -
 . 66
 - , 12

36.

, 21,
 - 5 - 4.
 6 - I AV (3), II AV (1)
 - - (2).

3 8
 , - (6.98%)
 (6.52%),

() . 12-
 23 - 11 (25.58%)

7 (15.22%)

5 (12.20%)

(1).


1.

3- 12-

(n = 130)		3	12
	43 (33.08%) 46 (35.38%) 41 (31.54%)	3 (6.98%) 3 (6.52%) 2 (4.88%)	11 (25.58%) 7 (15.22%) 5 (12.20%)

(47.8% : 30.4% : 21.7%) -

(1).



1.

12-

21

(OR: 24.61; 95% CI: 5.45, 111.21), 5

.
24 25 -

36-

(7)

- (2)

ABCD (2)

(4÷5 .)

: 4.1% -

2- , 5.9% - 7- 9.8% - 90-
130 ,

90-

3

ABCD (2) = 4 .

5 ABCD (2) = 5 . 6.2%.

ABCD (2) 4 .

7

4.2.

/

-

, ABCD (2)

257

24

:

:

119


(46.30%)

138

(53.70%)

42 89 .

(18.49%) , (n=45) 23 (16.67%) 22
 3 (6.67%) / - 2 (8.70%)
 1 (4.55%) . (n=33)
 / 21 (15.22%) 12 (10.08%), 2
 (6.06%) , 1 (4.76%) / 1 (8.33%) (
 2).



A.

B.

2 (A, B).

()

5.0% 6.67%.

35.51% (

75.51%),

- 34.45%.

- 10.15%

5.04%

- 15.22%

10.08%.


(p=0.01,

=0.05, F=10.41, SD=13.79)

(p<0.05, HSD [0.05]=24.35, HSD [0.01]=35.87).

ABCD (2)

(1÷3 .) - n=111 (43.19%)
 / 57 (41.30%) / 54 (45.38%). 4 (3.60%)
 , 2 (3.51%) 2 (3.70%)
 (4÷5 .) - n=128 (49.81%),
 71 (51.45%) / 57 (47.90%) -
 / - 7 (5.47%), 4 (5.63%) 3 (5.26%). -
 , 6 7 .
 - n=18 (7.0%), / 10 (7.25%) /8
 (6.72%) 4 (22.22%) - 3
 (30.0%) 1 (12.50%) (3).



A.

B.

3 (A, B).

()

ABCD (2).

90-

3.1%, 9.8% 17.8% (S.C. Johnston , 2007).
 : 3.60% (/ - 3.51% / 3.70%),
 5.47% (5.63% / 5.26%) 22.22% (30.0% / 12.50%).

ABCD (2)

($p=0.81$, $=0.05$). $(p=0.005$, $=0.05$, $F=50.33$, $SD=26.87$)
 $- 1 \div 3 \quad /6 \div 7 \quad .$ $- 4 \div 5 \quad /6 \div 7 \quad . (p<0.01$,
 $HSD [0.05]=24.59$, $HSD [0.01]=43.73$).

(D. Maslarov, D. Drenska, 2013-2015 .) ASCOD 1000


:

(A),
 (), () -
 (

r)
 (: $r=0.931$, $p=0.62$; : $r=0.924$, $p=0.85$; :
 $r=0.954$, $p=0.83$: $r=1.0$, $p=0.92$, $=0.05$).
 ()
 ($r=0.370$, $p=0.50$).

(4-) : - ,
 $r=0.099$, $r=0.300$, - , $r=0.407$, - A ,
 $r=0.548$, , $r=0.687$, , $r=0.677$, $r=0.693$, -

, $r=0.785$, $r=0.789$ - , $r=0.959$
 (2).
 (4-)
 : A , $r= -0.004$
 , $r= -0.006$ - A , $r=0.134$
 , $r=0.226$. (, $r=0.342$,
 $r=0.440$), (A , $r=0.558$, $r=0.600$), (,
 $r=0.773$) (, $r=0.946$)
 (3).



A.

B.

4 (A, B).

()

A-S-C-O-D.

2.

	1				
	0.548	1			
	0.687	0.785	1		
	0.099	0.677	0.407	1	
	0.300	0.959	0.693	0.789	1

3.

	1				
	0.558	1			
	0.134	0.226	1		
	-0.004	0.342	0.946	1	
	-0.006	0.773	0.440	0.600	1

Kappa

k=0.68 (95% CI 0.20-

0.25).

- k=0.70 (95% CI 0.21-0.27),

ASCOD.

(n=15)

($p=0.0000207$,

$=0.05$, $F=8.07$

SD

: 2.13

, 1.35 -

, 2.32 -

, 3.96 -

2.32

).

, <0.05

($p<0.01$, HSD [0.05]=2.62; HSD [0.01]=3.17 (

5).



5. n=15 5-

(n=9) ASCOD ($p=0.000351$, $=0.05$, $F=6.61$, $SD=2.95$).

, <0.05 , $p<0.01$, $HSD [0.05]=3.25$; $HSD [0.01]=3.95$.

(n=6) ($p=0.12$, $=0.05$, $F=2.03$, $SD=3.12$).

ASCOD ABCD (2) A3/A0 - S0/S0 -
C0/C0 - O2/O3 - D0/D0 ABCD (2)


(2015).

4

6.

4.

						ABCD (2)	
	1	0.374	-0.202	0.193	0.078	-0.133	0.216
	0.374	1	-0.267	0.036	0.274	0.562	-0.476
	-0.202	-0.267	1	0.347	-0.08	0.244	0.035
	0.193	0.036	0.347	1	0.242	0.095	-0.047
	0.078	0.274	-0.08	0.242	1	0	-0.323
ABCD (2)	-0.133	0.562	0.244	0.095	0	1	-0.381
	0.216	-0.476	0.035	-0.047	-0.323	-0.381	1



6.

(n=15)

(Multiple $r^2=0.45$, adj. Multiple $r^2=0.039$, $a=3.080$

,

):

-

ABCD (2)

($r= -0.381$)

-

:

-

($r=0.216$)

-

($r=0.035$).

-

($r= -0.476$),

-

($r= -0.047$)

-

($r= -0.323$).

-

ABCD (2)

-

-

($r=0.562$)

-

($r=0.244$),

($r=0.095$)

($r=0.0$).

ABCD (2)

($r= -0.133$).

4.3.

-

.

-

,

,

/

.

-

.

396

224

(56.57%)

.

-

172

43.43%,

2015 .

47 (27.33%)
 , 9 (5.23%) - , 14
 (8.14%) 12 (6.98%) -
 3- (1.74%)
 , 15 (8.72%) - , 9 (5.23%)
 , 4 (2.33%) - , 4 (2.33%) -
 1 (0.58%)
 54 (31.39 %)

- 73.2 ± 3.22 - - 68.6 ± 3.25 (p=0.01,
 =0.05).

(p=0.72), 3%

- (RR
 0.97, 95% CI 0.80-1.16).

(p<0.0001, OR 2.71, 95% CI 1.80-4.08), -

(p<0.0001, OR 4.39, 95% CI 2.81-6.84),

(p<0.0001, OR 5.89, 95% CI 2.71-12.80)

(p=0.05, OR 1.57, 95%

CI 1.01-2.44)

58%, 148%, 380%

38% - (

- 100%).

(p=0.78, OR 0.94, 95% CI 0.60-1.46)

(p=0.59, OR 0.89, 95% CI 0.60-1.34).

- (p<0.0001, OR 4.34, 95% CI 2.80-6.73)

($p < 0.0001$, OR 0.19, 95% CI 0.09-0.38)

($p = 0.01$, OR 0.56, 95% CI 0.37-0.86) -

(5).

5.

	$n = 224$	$n = 172$	<i>p</i> -value	Odds Ratio 95% Confidence Interval	Risk Ratio 95% Confidence Interval
	129 (57.59%)	41 (23.84%)	$p < 0.0001$	OR 4.34 (2.80 – 6.73)	RR 2.42 (1.81 - 3.23)
	57 (25.45%)	65 (37.79%)	$p = 0.01$	OR 0.56 (0.37 – 0.86)	RR 0.67 (0.50 - 0.90)
	38 (16.96%)	26 (15.12%)	$p = 0.62$	OR 1.15 (0.67 – 1.98)	RR 1.12 (0.71 - 1.77)
	42 (18.75%)	30 (17.44%)	$p = 0.74$	OR 1.09 (0.65 – 1.83)	RR 1.08 (0.70 - 1.64)
	11 (4.91%)	37 (21.51%)	$p < 0.0001$	OR 0.19 (0.09 – 0.38)	RR 0.23 (0.12 - 0.43)
()	103 (45.98%)	84 (48.84%)	$p = 0.57$	OR 0.89 (0.60 – 1.33)	RR 0.94 (0.76 - 1.16)

2


- 13 -

(6 7).

6.

ABCD (2)

	ABCD (2) - 1÷3 .	ABCD (2) - 4÷5 .	ABCD (2) - 6÷7 .
$n = 224$,	102	105	17
/ $n = 13$,	3 (2.94%)	6 (5.71%)	4 (23.53%)
$n = 172$ - ,	98	71	3
/ $n = 2$,	0 (0.0%)	1 (1.41%)	1 (33.33%)



7. -
ABCD (2).

ABCD (2)

(4÷5 .) - $p < 0.001$ (6÷7 .) - $p < 0.001$.

ABCD (2) - 1÷3 . , $p > 0.05$.

5. _____ :

5.1.

(H. Naess, 2006 ., V.S. Hedna, 2013 .)

-
(T.G. Phan
, 2012 .) -
(.
, 2007 .) (M. Selwaness
, 2014 .) ,

-
(S. Di Legge, 2005 ., C. Foerch, 2005 .)
(.
, 2016 .).
R. Sacco (2004 .)

Diagnosis of TIA (DOT) Score -

,
(D. Dutta, 2016

.).

(~30%)

-

16000

-

(E. Flossman & P.M.

Rothwell, 2003).

S. Ryoo , 2016 . -

PFO

, Q. Zeng , 2015 . 2245

-

-

-

(11)

(7)

(5).

-

12

-

(~20%).

LDL-

.)

55% 46% ,

(6.2%) - ABCD (2) (9.8%).

NORTHSTAR,

,

, . . .

60 .

- ABCD (2)

-

(A. Chandratheva , 2010 .)

ABCD (2)

,

-

7

,

,

5.2.

-

- 33.85%

, ()

(. , 2000).

- 75.51%

-

(J.P. Piccini, 2011 .,

A. Lasek-Bal, 2014 ., C. Bushnell, 2014 ., C.A. Emdin, 2014 .

). 2004 . T. Inoue 17%

1084

- :

28.02%. D.J. Ryan , 2015 .

-

,

.

-

.

12.84%.

ESUS

” ” , ,

PFO

(R.G. Hart, 2014).

(D.J. Gladstone, 2014, T. Sanna, 2014

).

($p=0.01$)

($p<0.05$).

K. Kimura, 1999.

60

ABCD (2)

: - 3.60% (3.51%/3.70%),
- 5.47% (5.63%/5.26%) - 22.22% (30.0%/12.50%),
3.1%, 9.8% 17.8% (S.C. Johnston, 2007).

90

, ABCD (2)

(R. Galvin, 2014).

ABCD (2)

($p=0.81$, =0.05).

(2011, 2012).

($p=0.005$)

($p<0.01$).

ASCOD

ASCO (P. Amarenco, 2009).

(M. Amort, 2012).

5-

ASCOD

:

-

-

($p>0.05$)

($r=0.931$),

($r=0.924$),

($r=0.954$)

($r=1.0$).

($r=0.370$).

-

, -

($r=0.785$)

($r=0.789$)

-

($r=0.959$)

-

-

A

($r= -0.004$)

($r= -0.006$)

-

($r=0.946$).

,

,

-

.

-

-

$k=0.68$

$k=0.70$,

.

:

A-S-C-O-D TOAST (.
, 2017).

5-

($p < 0.001$, $\alpha = 0.05$).

- (< 0.05).

($n = 15$) -

ASCOD

($n = 9$)

($p < 0.001$, $\alpha = 0.05$).

(< 0.05).

($n = 6$)

($p = 0.12$), . . .

, .

(2015).

2

(.)

ASCOD ABCD (2)

.

:

- (r = -0.381)

ABCD (2) -

-

:

- (r = 0.216)

- (r = 0.035),

.

,

1 (3.50%) 2 (12.45%)
1, 2 3 (0.0%)

ASCOD

- ABCD (2)

($r = -0.133$).

5.3.

- TIA-mimics

10% 48.5%

(M.L. Bots, 1997).

- 43.43%,

2015

- (~ 5)

M. Amort, 2011

A.

Noureddine

2014

:

($p < 0.0001$)

($p = 0.05$)

($p = 0.78$)

($p = 0.59$).

-

($p < 0.0001$),

($p < 0.0001$) (= $p = 0.01$).

(M. Amort, 2011 ., A. Nouredine, 2014 .)

: (-/), ,

60 .

ABCD (2)

($p < 0.001$)

-

ABCD (2) ($p > 0.05$).

, -

,

-

2 .

- :

(

20%)

- 24 .

6. _____ :

6.1. _____ :

:

1.

/

.

2.

: 3-

-

(

) 12-

-

,

3.

-

-

4.

:

5.

(

)

6.

,

7.

,

8.

-

,

-

6.2.

():

-

:

(3)

(>

3

)

ABCD (2)

-

ABCD (2)

-

-

-

,

,

ABCD (2).

-

-

-

:

7.

7.1.

()

1. . , . , . , D. Muresanu.
,
- , 2008, 8, . 2,
. 30-37.

2. . , . .
. .
, 2010, 6, . 1, . 43-49.

3. D. Maslarov, **D. Drenska**, J. Petrova. Early cerebrovascular disease - Clinical characteristics and Aspects. Description of a clinical case. American Journal of Neuroprotection and Neuroregeneration, 2010, vol. 2, 1, pp 71-77.

4. . , . , . . -
- .
, 2010, 10, . 2, . 54-57.

5. D. Maslarov, **D. Drenska**. Clinical analysis on neuroprotection of transient ischemic attacks. Neural Regeneration Research, 2011, 6 (10): 778-784.

6. D. Maslarov, **D. Drenska**. Association between ABCD (2) score, cerebral vascular territory, and dyslipidemia in patients with transient ischemic attack (Our Bulgarian Experience). Int Journal of Stroke, vol. 7, 6, August 2012, E1 (wileyonlinelibrary.com/journals/ijis).

7. . , . , . , . , . .

-
. . , V, 2013, 1 (6), . 16-19.

8. , 2014, 15, . 1, . 1-6.
 9. , 2014, . 7, XIV, . 16-19.
 10. MedPost, 2015, . 4, I, . 50-51.
 11. D. Maslarov, **D. Drenska**. Validation of the ASCOD Phenotyping in Bulgarian Patients with Stroke and Transient Ischemic Attack: A Retrospective Cohort Study. American Journal of Neuroprotection and Neuroregeneration, 2015, vol. 7, 1, pp 65-68.
 12. , 2016, 13, . 1, . 17-27, ISSN 1312-4676.
- 7.2. ,
1. , 14-16 2009, . 9, . 2, 11, . 64.
 2. , , 14-16 2009, . 9, . 2, 12, . 64.
 3. D. Maslarov, **D. Drenska**, J. Petrova. Early cerebrovascular events in patients with intracranial stenoses. 19th World Congress of Neurology, 24-30

October 2009, Bangkok, Thailand. Abstracts in Journal of Neurological Sciences, vol. 285, P O01-MO-15, p. S159.

4. . , .
:

, 2-3 2010, , .
, 6, .2, 01, .3.

5. . , .

.
, . . , 19-21 2011, .
, 11, .2, 5, .80-81.

6. . , .

– .
«
– », , 2012, . , ,
3, 7, , .190-194.

7. . , .

– .
« –
», , 2012, . , , 3,
7, .532-534.

8. D. Maslarov, **D. Drenska**. Therapeutic effects of Atorvastatin (Torvacard®) in patients with dyslipidemia and cerebrovascular disease. 32nd Balkan Medical Week, Balkan Medical Union, 21-23 September 2012, Nish, Abstr. Book, P 151.

9. **D. Drenska**, D. Maslarov. Limb shaking transient ischemic attacks, associated with extra- and intracranial occlusive disease and migraine – report of two cases. 32nd Balkan Medical Week, Balkan Medical Union, 21-23 September 2012, Nish, Abstr. Book, P 181.

10.
 -
 , 16-19 2013, , 14, . 2,
 , . 69-70.
11. ABCD (2) -
 , 16-19 2013, , 14, . 2, 13,
 . 78.
12.
 - , 16-19
 2013, , 14, . 2, 18, . 80.
13.
 , 12-15 2014, , 15, . 1,
 2, . 95-96.
14.
 , 12-15 2014,
 , 15, . 1, 2, 101, . 100.
15.
 , 12-15 2014, , 15, . 1,
 2, 10, . 142-143.
16.
 (Telestroke): -
- XIV

, 07-10 2015, . , 16, . 1,
1, , . 66.
17. . , . .
ASCOD –
(). XIV
, . . , 07-10 2015, .
, 16, . 1, 1, 101, . 70.
18. . , . . - .
XIV , . .
, 07-10 2015, . , 16, . 1,
1, 464, . 102.
19. . , . . . XV
, . . .
, 02-05 2016, . , 17, . 1,
1, 108, . 80.
20. . , . , . .
-
. XV
, . . , 02-05 2016, . ,
17, . 1, 1, , . 77.